Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · Real-Time Price · USD
19.68
-1.00 (-4.84%)
Sep 29, 2026, 3:15 PM EDT - Market open
Anika Therapeutics Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Anika Therapeutics stock has a consensus rating of "Buy" and an average price target of $22. The average 1-year stock price forecast is 11.79% higher than the current stock price, while the lowest is $21 (+6.71%) and the highest is $23 (+16.87%).
Price Target: $22 (+11.79%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Anika Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Apr '26 | Jul '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Buy Initiates $21 → $23 | Buy | Initiates | $21 → $23 | +16.87% | Sep 18, 2026 |
| Barrington | Barrington | Buy Maintains $17 → $21 | Buy | Maintains | $17 → $21 | +6.71% | Jul 30, 2026 |
Financial Forecast
Revenue This Year
121.64M
from 112.82M
Increased by 7.82%
Revenue Next Year
128.26M
from 121.64M
Increased by 5.44%
EPS This Year
1.05
from 0.11
Increased by 854.55%
EPS Next Year
0.95
from 1.05
Decreased by -9.52%
EPS and Forward PE are based on non-GAAP adjusted numbers.